Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Clinical study evaluating selective or nonselective beta blockers use and fracture risk in patients with primary osteoporosis
Clinical study evaluating selective or nonselective beta blockers use and if there is fracture risk in patients with primary osteoporosis
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| nonselective beta blocker group | Experimental | Twenty patients with osteoporosis and hypertension on the same treatment as control group in addition to propranolol (Inderal®) 10 mg once daily titrated as patient's response. |
|
| cardio-selective beta blocker group | Experimental | Twenty patients with osteoporosis and hypertension on the same treatment as control group in addition to bisoprolol (Concor®) 5 mg once daily titrated as patient's response. |
|
| Control group | Placebo Comparator | Ten patient with osteoporosis on alendronate sodium 70 mg (Fosamax®) once/week, vitamin D3 1 mcg once daily and calcium supplement 500 mg once daily. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| nonselective beta blocker | Drug | nonselective beta blocker |
|
| Measure | Description | Time Frame |
|---|---|---|
| Number of patients with fracture in each group | the exact number of patients with fracture in each group | 1 year |
Not provided
Not provided
Inclusion Criteria:
• Male & female osteoporotic patient aged ≥ 50 years
Exclusion Criteria:
Patients on drugs that may improve osteoporosis disease state such as:
Patients on drugs that may worsen osteoporosis disease state such as:
• Corticosteroids, Loop diuretics, Anticonvulsants, Antidepressants, Aromatase inhibitors, Thyroid replacement therapy and Proton pump inhibitors.
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Sherief Abd-Elsalam, ass. prof. | Contact | 00201147773440 | sheriefabdelsalam@yahoo.com |
| Name | Affiliation | Role |
|---|---|---|
| Mona Abd El-Rafea Abdo, PH D | Clinical Pharmacy Department, Faculty of Pharmacy, Tanta University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Sherief Abd-Elsalam | Recruiting | Tanta | 35127 | Egypt |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D011433 | Propranolol |
| D017298 | Bisoprolol |
| D019386 | Alendronate |
| ID | Term |
|---|---|
| D050198 | Phenoxypropanolamines |
| D011412 | Propanolamines |
| D000605 | Amino Alcohols |
| D000438 | Alcohols |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| cardio-selective beta blocker group | Drug | cardio-selective beta blocker group |
|
|
| alendronate sodium | Drug | alendronate sodium |
|
|
| D009930 |
| Organic Chemicals |
| D020005 | Propanols |
| D000588 | Amines |
| D009281 | Naphthalenes |
| D011084 | Polycyclic Aromatic Hydrocarbons |
| D006841 | Hydrocarbons, Aromatic |
| D006844 | Hydrocarbons, Cyclic |
| D006838 | Hydrocarbons |
| D011083 | Polycyclic Compounds |
| D004164 | Diphosphonates |
| D063065 | Organophosphonates |
| D009943 | Organophosphorus Compounds |